1. Home
  2. SLNH vs EQ Comparison

SLNH vs EQ Comparison

Compare SLNH & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soluna Holdings Inc.

SLNH

Soluna Holdings Inc.

HOLD

Current Price

$1.15

Market Cap

184.6M

Sector

Technology

ML Signal

HOLD

Logo Equillium Inc.

EQ

Equillium Inc.

HOLD

Current Price

$2.26

Market Cap

157.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLNH
EQ
Founded
1961
2017
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
184.6M
157.4M
IPO Year
2005
2018

Fundamental Metrics

Financial Performance
Metric
SLNH
EQ
Price
$1.15
$2.26
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$5.00
$8.00
AVG Volume (30 Days)
9.4M
504.8K
Earning Date
05-15-2026
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
80.41
N/A
EPS
N/A
N/A
Revenue
$38,021,000.00
$41,095,000.00
Revenue This Year
$55.83
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
80.49
N/A
52 Week Low
$0.43
$0.76
52 Week High
$5.14
$3.54

Technical Indicators

Market Signals
Indicator
SLNH
EQ
Relative Strength Index (RSI) 43.43 45.38
Support Level $1.07 $1.68
Resistance Level $1.41 $2.61
Average True Range (ATR) 0.10 0.19
MACD 0.00 0.03
Stochastic Oscillator 21.43 50.00

Price Performance

Historical Comparison
SLNH
EQ

About SLNH Soluna Holdings Inc.

Soluna Holdings Inc is a U.S.-based company engaged in the development and operation of data centers powered by renewable energy. The company utilizes excess or curtailed energy from renewable sources to support high-performance computing applications, including cryptocurrency mining, artificial intelligence, and machine learning. Its business model focuses on converting underutilized renewable energy into computing resources through co-located data center infrastructure.

About EQ Equillium Inc.

Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.

Share on Social Networks: